Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 3, 2010New England Journal of MedicineOpen Access

Safety of Recombinant Activated Factor VII in Randomized Clinical Trials

View Full Paper
Ask AI
Bookmark
Share

Authors

Marcel LeviMarcel LeviVascular MedicineJLJerrold H. LevyCardiac SurgeryHAHenning Friis AndersenNational Health Service

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Levi et al. (2010) studied this question.

synapsesocial.com/papers/69d80adb45af6083e6ae2ac2https://doi.org/10.1056/nejmoa1006221
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers2002 · 322 citations
  2. 2Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage2005 · 1,171 citations
  3. 3Recombinant Coagulation Factor VIIa in Major Liver Resection2005 · 199 citations
  4. 4Safety and Efficacy of Recombinant Activated Factor VII2009 · 274 citations
  5. 5A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects2005 · 62 citations